Current and future directions in mammalian target of rapamycin inhibitors development

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.3, 2011-03, pp. : 381-394

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of the mammalian target of rapamycin

By Dancey Janet E

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 313-328

Informa Healthcare

Access to resources Recommend Favorite

Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 8, 2016-09 ,pp. : 945-955

Bentham Science Publishers

Access to resources Recommend Favorite

Angiogenesis Inhibitors: Current & Future Directions

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 1-9

Bentham Science Publishers

Access to resources Recommend Favorite

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

By Nelson Valerie Altman Jessica K Platanias Leonidas C

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 715-722

Informa Healthcare

Access to resources Recommend Favorite

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

By Albert Sébastien Serova Maria Dreyer Chantal Sablin Marie-Paule Faivre Sandrine Raymond Eric

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 919-930

Informa Healthcare

Access to resources Recommend Favorite